Prescribing Vortioxetine

At a glance

Niche multimodal antidepressant for depression with cognitive fog or SSRI sexual dysfunction; no more effective than a generic SSRI.

How to doseFull section

Comes as

Tablet5, 10, 20 mg

Example photos; looks vary by maker. Click to enlarge.

In shortThe label starts at 10 mg and goes up to 20 mg as tolerated; many clinicians start at 5 mg, and most patients stabilize at 5 to 10 mg.

FDA labelIn practice

A row across both columns means the label and usual practice agree. Off-label marks the few places where practice goes beyond what the label allows.

Adultsmajor depressive disorder

StartFDA labelRecommended starting dose: 10 mg once daily, without regard to meals.In practiceOpening at 5 mg instead is gentler on the gut and costs little time.

IncreaseFDA labelThen increase to 20 mg a day as tolerated.In practiceGenerally about a week or more between steps: 5 mg, then 10 mg, then 20 mg, as tolerated. There is no rush; response takes weeks regardless.

Above 20 mg a dayFDA labelThe efficacy and safety of doses above 20 mg a day have not been evaluated in controlled clinical trials.

Lower doseFDA labelA dose decrease down to 5 mg a day may be considered for patients who do not tolerate higher doses.In practiceA large share of patients never comfortably reach 20 mg. Nausea caps many patients at 5–10 mg, which is often fine.

MaintenanceFDA labelNo labeled doseIn practiceMost patients stabilize at 5–10 mg a day, and 20 mg is not needed to keep someone well.

Older adultsFDA labelNo dose adjustment is recommended on the basis of age.In practiceStart low (5 mg) and go slowly. Watch GI tolerance.

Interacting drugs and CYP2D6FDA labelPoor metabolizers: maximum 10 mg a day. Strong CYP2D6 inhibitor: reduce the dose by one-half.In practiceOff-labelCap at 10 mg a day with a strong 2D6 inhibitor, instead of halving, or in a poor metabolizer.

StoppingFDA labelIt is recommended that the dose be decreased to 10 mg a day for one week before full discontinuation of 15 or 20 mg a day.In practiceLonger use: a modest taper, e.g. 20 to 10 to 5 mg over 1–2 weeks. Off-label Short courses can often stop without an elaborate taper.

Switching to or from an MAOIFDA labelAt least 14 days from an MAOI intended to treat psychiatric disorders to vortioxetine. At least 21 days from vortioxetine to such an MAOI.

Timing with foodFDA labelStarting dose: once daily, without regard to meals.In practiceTaking it with food or a snack meaningfully reduces the nausea.

Nausea is frequently what limits the dose; taking it with food or a snack meaningfully reduces it.

IndicationsFull section

FDA-approved

Major depressive disorder, adults

Boxed warningsFull section

Suicidality in patients under 25Not approved <18; monitor early in treatment and at dose changes

ContraindicationsFull section

MAOIsWithin 14 days; allow 14 days in each direction (serotonin syndrome)

MonitorFull section

Mood, cognition, sexual functionBaseline (ASEX or CSFQ if sexual function is the target), then each follow-up

Nausea, GI toleranceEach follow-up; advance only when the gut settles

SuicidalityEarly in treatment and at dose changes

Activation, maniaScreen for bipolarity first; then ongoing

Serotonin syndromeWhen combined with other serotonergic drugs

No routine labs, ECG, BP or metabolic monitoring; no renal or hepatic dose change.

Drug interactionsFull section

Drug-drug

MAOIsContraindicated: serotonin syndrome; 14-day washout in each direction

Strong 2D6 inhibitorsBupropion, fluoxetine, paroxetine, quinidine raise levels; cap at 10 mg/day, watch tolerability

SSRIs/SNRIs, tramadol, triptansAdditive serotonin-syndrome risk; combine cautiously and counsel

Linezolid, methylene blue, St. John's wortAdditive serotonin-syndrome risk; combine cautiously and counsel

Rifampin, carbamazepine, phenytoinCan lower levels; consider up to 3× the dose, reduce back within 14 days of stopping

NSAIDs, anticoagulants, antiplateletsWeak platelet-aggregation impairment; watch for bleeding

CNS depressants, alcoholAdditive effects; counsel

CYP enzymes

CYP2D6Substrate, primary clearancePoor metabolizer or strong 2D6 inhibitor: cap at 10 mg/day

CYP3A4Substrate, secondaryStrong CYP inducers can lower levels (see interactions)

Not a meaningful CYP inhibitor: clean with tamoxifen, TCAs, beta-blockers, antipsychotics, opioids.

Must counselFull section

NauseaCommon early; take it with food, it often eases over the first weeks

Sexual side effectsLess likely at low doses; tell me if they appear

Headache, dizzinessCommon, usually mild and short-lived

BleedingTake care with NSAIDs and blood thinners; tell me what you take

StoppingWithdrawal is mild, but we step the dose down rather than stop cold

Suicidal thoughtsCall right away if new or worse, especially under 25

PearlsFull section

SERT occupancy ~50/65/80% at 5/10/20 mg sits below SSRI territory at 5–10 mg: sexual sparing is a low-dose advantage that erodes at 15–20 mg.

Switching SSRI-induced sexual dysfunction to vortioxetine beat escitalopram (NNT ~12); keep the dose low or you reintroduce the problem.

The cognitive benefit is real but small and narrow: a DSST gain of ~2–4 points, no effect on Stroop, Trails B or verbal recall.

Unlike most SSRIs, efficacy looks dose-dependent, but nausea caps many patients at 5–10 mg, which is often fine.

Not for TRD, GAD as a primary target, ADHD or binge eating. Not a CYP inhibitor, so it is clean with tamoxifen, TCAs and beta-blockers.

Summary of this guide. Check the full sections before prescribing.

Photo credits

Trintellix (vortioxetine) 10 mg tablets: Garzfoth, CC BY-SA 4.0, Wikimedia Commons

Vortioxetine 5 mg, box and tablets (sold in Europe as Brintellix): Syd Storm, CC0, Wikimedia Commons

Vortioxetine 5 mg blister pack (Brintellix): Syd Storm, CC0, Wikimedia Commons

Why Vortioxetine Matters (and Where the Hype Ends)

Vortioxetine is the most pharmacologically interesting antidepressant to reach the market in the last generation. It is a multimodal serotonin modulator that acts at six different serotonin targets, and it is also one of the most oversold. Stripped of the marketing, it is no more effective than a generic SSRI for core depressive symptoms, but it has two clinically usable advantages. It causes less sexual dysfunction (especially at 5 to 10 mg), and it has a small but real signal for processing-speed cognition. You pay for them with dose-limiting nausea and a brand-name price.

Those two advantages matter. Sexual dysfunction and the "brain fog" of depression are two of the most common reasons patients abandon otherwise-effective antidepressants, and vortioxetine is a targeted tool for exactly those patients. It is not a smarter, stronger, or broadly better antidepressant, though, and prescribing it as if it were will waste money and disappoint patients.

It launched in September 2013 as Brintellix and was renamed Trintellix in 2016, after an FDA safety alert in 2015 flagged dangerous confusion with the antiplatelet drug Brilinta (ticagrelor). The molecule never changed.

Part 1: Indications

FDA-Approved Use

• Major Depressive Disorder in adults (approved 2013)

That is the entire approved label. In February 2016 an FDA advisory committee voted 8 to 2 that the sponsors had shown substantial evidence of an effect on certain aspects of cognitive dysfunction in MDD. The FDA did not agree, issuing complete response letters in March 2016 and June 2017, and the cognitive data reached the Clinical Studies section of the label only in May 2018. There is still no standalone cognition indication, and the label adds that the effects seen may reflect improvement in depression.

Where It Earns Its Place

Depression with prominent cognitive complaints. This is vortioxetine's defining niche. Depression impairs attention, memory, and processing speed to a degree one study equated with roughly 24 hours of sleep deprivation, and "diminished ability to think or concentrate" is a formal DSM-5 criterion. Vortioxetine improved the Digit Symbol Substitution Test (DSST), a two-minute measure of processing speed and attention. Pooling the three placebo-controlled trials that used it (n=1,652), the standardized effect against placebo was 0.35, falling to 0.24 once change in depression score was taken out. Duloxetine, the active reference in two of those trials, did not separate from placebo on the DSST. More important, path analysis suggests roughly 76% of the cognitive benefit is independent of mood improvement (vs. roughly 50% for duloxetine), which implies a direct pro-cognitive action rather than "the depression just got better."

Depression where sexual dysfunction is the dealbreaker. This is the other real niche. In the pivotal switch trial (Jacobsen 2015), 447 patients with SSRI-induced sexual dysfunction were switched to vortioxetine (10 to 20 mg) or escitalopram (10 to 20 mg); vortioxetine produced significantly greater improvement in sexual functioning (CSFQ +8.8 vs +6.6, p=0.01), with an NNT of about 12 for sexual-function recovery. For a patient who got mood benefit from an SSRI but quit over sexual side effects, vortioxetine is a rational switch target.

Geriatric depression. Efficacy is comparable to duloxetine in older adults. In the one geriatric head-to-head, only vortioxetine (not duloxetine) improved the DSST, a potential edge when late-life depression comes with cognitive slowing.

Patients with a history of antidepressant discontinuation syndrome. Because of its very long half-life (about 66 hours) and multimodal profile, vortioxetine has minimal discontinuation syndrome. That helps the patient burned by paroxetine or venlafaxine withdrawal.

Emerging / Off-Label (Thin Evidence)

• Adjunctive for schizophrenia negative symptoms: one 78-patient trial (add-on to risperidone, 20 mg/day) showed a large effect (0.97) on negative symptoms over 8 weeks, no effect on positive symptoms (Moazen-Zadeh 2020). Interesting, but a single study that shouldn't change practice.
• Age-related cognitive decline in non-depressed elderly: 100 patients over 65 with subthreshold cognitive complaints; vortioxetine plus computerized cognitive training beat placebo at 3 months (effect size 0.6). Promising, but it needs replication.

Where It Fails

• Treatment-resistant depression: never properly studied for TRD; did not beat duloxetine or sertraline head-to-head. The one flattering TRD-like result (70% vs 56% response vs agomelatine) used a single-failure definition and a non-standard comparator, and it was never replicated. It has no established role as a switch/augmentation strategy.
• Generalized anxiety disorder as a primary target: one positive study, then three failed RCTs. The pooled effect size is a trivial 0.12, and remission is no better than placebo. Anxiety improves only insofar as the depression does.
• Adult ADHD: failed a 3-month RCT (Biederman 2019), despite the cognitive marketing.
• Binge-eating disorder: failed a small RCT (Grant 2019).

Part 2: Before You Start

Vortioxetine needs very little workup before you start, one of its practical virtues.

• No mandatory baseline labs.
• No baseline or periodic ECG: no QT-prolongation signal, no cardiac monitoring required (contrast citalopram).
• No metabolic monitoring driven by the drug itself; it is weight-neutral.

What's worth doing before you start:

• Document a baseline of the two things you're treating with this drug: mood and cognitive complaints (ask specifically about processing speed, concentration, word-finding), plus sexual function if that's the reason you're choosing it. If you'll want to claim a benefit later, measure it now: an ASEX or CSFQ for sexual function takes two minutes.
• Confirm no MAOI within the prior 14 days (and don't start an MAOI until about 14 days after stopping vortioxetine) because of serotonin-syndrome risk.
• Screen for bipolarity, as with any antidepressant, before monotherapy.
• Ask about strong CYP2D6 inhibitors already on board (bupropion, fluoxetine, paroxetine, quinidine); they change your dosing ceiling (see Interactions).

Who Is a Poor Candidate?

• Patients who cannot tolerate GI side effects, or for whom nausea would be especially destabilizing.
• Cost-sensitive patients when a generic SSRI/SNRI would do; the first question with vortioxetine is often, "is there a specific reason not to use a generic?"
• MAOI use within 14 days (absolute).

Part 3: How to Start and Dose

Formulation

Oral tablets: 5, 10, and 20 mg, dosed once daily with or without food. Taking it with food or a snack meaningfully reduces the nausea. That is the single most useful practical tip for getting patients to a therapeutic dose.

Dosing in Practice

The label and the exam room diverge. Nausea is dose-dependent and frequently dose-limiting, so a large share of patients never comfortably reach 20 mg. As one expert (Gitlin) put it: "the GI side effects have precluded my ability to get to 20 mg with regularity, so I have a number of people at 5 or 10 mg."

Serotonin Transporter Occupancy by Dose

This table is the mechanistic key to the whole drug. At 5 to 10 mg it sits below the roughly 80% SERT occupancy where classic serotonergic side effects (sexual dysfunction in particular) take off. That is why it spares sexual function at low-to-mid doses and loses that edge as you climb toward 20 mg.

Maintenance

• Most patients stabilize clinically at 5 to 10 mg.
• In the label's non-US maintenance trial, remitted patients continued on a fixed 5 or 10 mg a day and went longer before recurrence than those moved to placebo. You do not need to be at 20 mg to keep someone well.

Dose Adjustments and Special Populations

• Hepatic / renal impairment: no dose adjustment for any degree of renal impairment or for mild-to-severe hepatic impairment.
• Pediatric: not FDA-approved for MDD (pediatric MDD efficacy was not established).

Part 4: Monitoring

Monitoring is simple:

• No routine labs. You don't need an ECG, blood pressure monitoring (unlike the SNRIs), or a weight/metabolic panel driven by the drug.
• Do reassess the things you're targeting. At follow-up, re-ask about mood, cognitive symptoms, sexual function, and GI tolerance. If you chose vortioxetine for cognition, remember the cognitive-decline data required about 3 months to show effect; don't declare failure on the cognitive front too early.
• Standard antidepressant vigilance: monitor for emergent suicidality (boxed warning applies), activation/mania, and, as with any serotonergic, serotonin syndrome if combined with other serotonergic agents.

Part 5: Side Effects and How to Manage Them

Vortioxetine differs from most antidepressants here: its problem isn't sedation, weight, or cardiac risk. It's the gut, and GI intolerance is the reason patients quit or can't titrate.

Gastrointestinal

Nausea is the most common and most dose-limiting side effect. It is dose-dependent, reported in roughly 20 to 30% (about 25%) of patients, and the single biggest obstacle to reaching 20 mg. Vomiting, diarrhea, and constipation also occur (dose-dependent, especially at or above 20 mg). In head-to-head class data, vortioxetine ranks among the worst antidepressants for nausea (OR ~4.3, comparable to duloxetine).

Management:

• Take with food or a snack: the most effective single measure.
• Titrate slowly: hold at 5 mg longer, advance only when the gut settles.
• Nausea often attenuates over the first weeks; counsel patients to push through the early period if they can.
• For persistent nausea, an antiemetic such as ondansetron can bridge the titration (no tardive-dyskinesia risk, unlike dopamine antagonists).
• If GI intolerance limits the dose, stay at the tolerated dose: 5 to 10 mg still treats depression and still spares sexual function.

Sexual Function (Dose-Dependent)

Sexual sparing is vortioxetine's selling point and where it differs, but be precise about the claim:

• At 5 to 10 mg: treatment-emergent sexual dysfunction is effectively non-inferior to placebo. This is the real advantage.
• At 15 to 20 mg: rates climb toward other antidepressants; pooled data show roughly 43 to 46% (vs about 32% placebo), numerically higher but not statistically significantly so, and still lower than duloxetine's roughly 48% (which was significantly above placebo).
• Switching an SSRI patient with sexual dysfunction to vortioxetine improves sexual function (NNT ~12 vs escitalopram).

Weight and Metabolic

Vortioxetine is weight-neutral, with negligible weight gain in trials. That is a real advantage over mirtazapine, and it does better than several SSRIs/SNRIs. There is no adverse lipid or glucose signal attributable to the drug.

CNS / Neuropsychiatric

• Headache and dizziness: common, usually mild and transient.
• No sedation reported; the drug is neither sedating nor markedly activating.
• Standard antidepressant class effects apply: monitor for emergent suicidality, and for activation/switch in undiagnosed bipolar patients.

Cardiac

• No QT prolongation and no ECG changes. It has one of the cleaner cardiac profiles among antidepressants, which helps in cardiac patients where citalopram/escitalopram give pause.

Part 6: Overdose, Toxicity, and Boxed Warning

• Overdose: data are limited, but vortioxetine appears relatively benign in overdose. The main concern is serotonin syndrome, particularly in combination with other serotonergic drugs. No specific antidote; management is supportive.
• No cardiac lethality signal (no QT effect), an advantage over tricyclics and citalopram in overdose.

Part 7: Drug Interactions

Vortioxetine is a substrate and not a major inhibitor, so it's cleaner than fluoxetine/paroxetine/fluvoxamine for polypharmacy, but its own levels can be pushed around.

Pharmacokinetic: What Changes Vortioxetine's Level

• Metabolized primarily by CYP2D6 (with CYP3A4 secondary). This has two consequences:
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine) raise vortioxetine levels. With a strong 2D6 inhibitor on board, or in a known CYP2D6 poor metabolizer, cap the dose (commonly at 10 mg) and watch tolerability.
  • Strong CYP inducers (rifampin, carbamazepine, phenytoin) can lower levels; a dose increase may be needed if co-prescribed.
• Vortioxetine itself does not meaningfully inhibit CYP enzymes. That gives it an edge over the 2D6-inhibiting SSRIs when the patient is on tamoxifen, tricyclics, beta-blockers, antipsychotics, or opioids.

Pharmacodynamic: Serotonergic Additivity

• MAOIs: contraindicated together; 14-day washout in each direction.
• Other serotonergics (SSRIs/SNRIs, tramadol, triptans, linezolid, methylene blue, St. John's wort): additive serotonin-syndrome risk; combine cautiously and counsel patients.
• Bleeding risk: as a serotonergic agent it can weakly impair platelet aggregation; watch with NSAIDs, anticoagulants, and antiplatelets.
• CNS depressants / alcohol: additive effects; counsel.

Part 8: Special Populations

Pregnancy

Human data are limited (historically FDA Pregnancy Category C, before the categories were retired). There is no strong signal of teratogenicity, but the evidence base is far thinner than for sertraline, which remains the default when an SSRI in pregnancy is acceptable. As with all late-third-trimester antidepressant exposure, watch the neonate for transient adaptation/discontinuation symptoms and, with any serotonergic, the small PPHN consideration. In practice, reserve vortioxetine in pregnancy for a woman who specifically needs this drug's profile and did poorly on better-studied agents; it's rarely a first choice for a newly pregnant patient.

Lactation

Data are sparse. Most authorities favor better-characterized agents (sertraline) for breastfeeding. If vortioxetine is continued, monitor the infant clinically.

Elderly (65 and Older)

• Efficacy comparable to duloxetine; a possible cognitive edge (DSST) in this group.
• Start low (5 mg), go slow, as with any antidepressant in older adults, and watch GI tolerance.
• No age-specific mandatory dose cap, but polypharmacy and CYP2D6 interactions matter more here.

Renal and Hepatic Impairment

• No dose adjustment is required for any degree of renal impairment or for mild, moderate or severe hepatic impairment, a practical advantage, and unlike duloxetine (hepatic cautions) or the SNRIs (renal/BP concerns).

Pediatric

• Not FDA-approved under 18; no established pediatric efficacy. Off-label use is not supported by the evidence here.

Part 9: Discontinuation

Easy discontinuation is an overlooked advantage. Because of its roughly 66-hour half-life and multimodal profile, vortioxetine has minimal discontinuation syndrome, among the lowest of any antidepressant and similar in spirit to fluoxetine's long-half-life protection.

• For short courses, it can often be stopped without an elaborate taper.
• For longer-term use, a modest taper (for example, over one to two weeks, stepping down 20 → 10 → 5 mg) is still sensible and comfortable, but abrupt cessation is far better tolerated than with paroxetine, venlafaxine, or duloxetine.
• This makes vortioxetine a rational choice for the patient with a history of bad SSRI/SNRI withdrawal.

Part 10: Vortioxetine vs the Alternatives

Efficacy for core depression is a wash across the modern antidepressants: an industry meta-analysis (Llorca 2014) concluded vortioxetine is no more effective than other antidepressants, and in head-to-heads it did not beat duloxetine, venlafaxine, or sertraline on mood. So you choose among them on side effects and niche fit:

• vs SSRIs (generic): similar mood efficacy; vortioxetine's edge is less sexual dysfunction at 5 to 10 mg and a DSST cognitive signal SSRIs don't have (SSRIs were neutral-to-negative on DSST across 9 prior trials). SSRIs win decisively on cost and familiarity. Reach for vortioxetine when the SSRI's sexual or cognitive downside is the specific problem.
• vs Duloxetine: duloxetine is at least as effective (arguably better) for mood, but duloxetine did not separate from placebo on the DSST in the trials that tested both, and vortioxetine has less sexual dysfunction and no hepatic-with-alcohol caution. For medically complex patients, some experts prefer desvenlafaxine over either.
• vs Bupropion: if the goals are sexual sparing, cognition/energy, and weight, bupropion arguably does all three at least as well and much cheaper (no sexual dysfunction at all, activating, weight-neutral-to-loss, some cognitive data). Bupropion's downsides are anxiety/insomnia activation and seizure-threshold caution. For a patient whose main issue is sexual side effects, bupropion is often the better and cheaper first move; vortioxetine is the serotonergic alternative when you still want serotonergic coverage (for example, prominent anxiety).
• vs Vilazodone: similar marketing (SERT inhibition plus 5-HT1A agonism), but vilazodone lacks vortioxetine's cognitive data, and its claimed faster-onset/anti-anxiety advantages were never substantiated.
• vs Mirtazapine / Trazodone: those are your choices when insomnia, appetite loss, or sedation is the target. Vortioxetine is the opposite profile: non-sedating, weight-neutral.

Vortioxetine is underused for the right reasons and overused for the wrong ones. The branded cost and frequent nausea rightly keep it off the first-line default, but its two real advantages (low-dose sexual sparing, processing-speed cognition) go unused by the clinicians who wrote it off entirely. Match it to the patient.

Mechanism

Vortioxetine is a multimodal serotonin modulator ("serotonin modulator and stimulator"), not a plain SSRI. It combines:

• Serotonin reuptake inhibition (SERT): the primary, SSRI-like action (50/65/80% occupancy at 5/10/20 mg)
• 5-HT1A agonism: thought to contribute to sexual sparing and to antidepressant effect
• 5-HT1B partial agonism
• 5-HT1D antagonism
• 5-HT3 antagonism: this doesn't spare the gut, though; nausea is still common
• 5-HT7 antagonism: the receptor most implicated in the pro-cognitive effects (learning/memory in animal models)

Preclinically it induces neurogenesis in mice, a plausible (unconfirmed-in-humans) substrate for the cognitive signal. Its half-life is long, roughly 66 hours, which is why it is dosed once daily and discontinuation is mild. It is cleared mainly by CYP2D6, with CYP3A4 secondary. The multi-receptor profile is the reason it "doesn't feel like an SSRI": more GI upset, less sexual dysfunction at low dose, and a cognitive edge no pure SSRI matches.

The Bedside Cheat Sheet